Form 4: Astera Labs Director Sells Shares Under 10b5-1 Plan

Astera Labs Director Jack R. Lazar reported a future sale of 2,500 shares of common stock for $130 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Director Jack R. Lazar of Astera Labs, Inc. (ALAB) reported a planned sale of common stock.
• The transaction involves 2,500 shares to be sold at a price of $130 per share.
• The sale is scheduled for March 16, 2026, and is part of a Rule 10b5-1 trading plan adopted on December 2, 2025.
• Following this planned transaction, Jack R. Lazar will directly beneficially own 84,851 shares of Astera Labs common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale, its execution under a pre-arranged 10b5-1 plan and its future date mitigate concerns about immediate negative sentiment, as it reflects personal financial planning rather than a reaction to new information.

Negatives

• An insider, Director Jack R. Lazar, is planning to sell 2,500 shares of common stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a pre-arranged Rule 10b5-1 plan, are common for executives and directors to manage personal finances and diversify holdings without being accused of trading on material non-public information. This specific transaction for Astera Labs is a routine disclosure of a future planned sale.

Related Party Transactions

• Director Jack R. Lazar plans to sell 2,500 shares of Astera Labs common stock at $130 per share on March 16, 2026, under a Rule 10b5-1 trading plan.

Stakeholder Impact

• Shareholders may interpret the planned insider sale differently; some might see it as a negative signal, while others recognize it as routine diversification under a 10b5-1 plan.

Key Dates

Recommendation

The planned sale by Director Jack R. Lazar is a pre-scheduled transaction under a Rule 10b5-1 plan, indicating personal financial management rather than a reaction to new material information. This type of routine insider activity, especially one dated in the future, generally does not provide a strong signal for a change in investment strategy, thus a 'hold' recommendation is appropriate.

Keywords

Astera Labs, ALAB, Form 4, Insider Sale, Jack R. Lazar, 10b5-1 Plan, Director, Common Stock